Long-term data support use of growth hormone in adults with GHD
Using data from 15,809 adult patients treated with growth hormone (GH) replacement, researchers determined that the long-term use of GH replacement is safe in these patients.
Data from a cohort of patients from the global observational KIMS study treated with GH and followed through routine clinical practice was analyzed to evaluate safety, including adverse events (AEs) and clinical characteristics.
Patients had a mean follow-up of 5.3 years. Overall, 51.2% of patients reported AEs, with 18.8% related to treatment. Patients who were older, had GHD due to pituitary/hypothalamic tumors, or adult-onset GHD had higher crude AE rates. There was no correlation with GH dose and AE rate. Overall, 606 deaths were reported, including 146 by neoplasms, 71 by cardiac/vascular disorders, and 48 by cerebrovascular disorders.
The incidence of de novo cancer was comparable to that in the general population; it was significantly lower in patients with idiopathic/congenital GHD and similar in those with pituitary/hypothalamic tumors or other etiologies.
Neutral effects were seen in lipids/fasting blood glucose levels.
Johannsson G, Touraine P, Feldt-Rasmussen U, et al. Long-term safety of growth hormone in adults with growth hormone deficiency: Overview of 15,809 GH-treated patients. J Clin Endocrinol Metab. 2022;dgac199. doi: 10.1210/clinem/dgac199. Epub ahead of print. PMID: 35368070.